25 /100
LOW RISK
Score updated Jul 14, 2026

ZBIO — Zenas BioPharma, Inc. Dilution Risk Tracker

Track ZBIO dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ZBIO — Get alerts when the score changes →

As of July 14, 2026, Zenas BioPharma, Inc. (ZBIO) has a DilutionWatch DilutionScore of 25/100, rated LOW dilution risk. Zenas BioPharma, Inc. has a market capitalization of $1.16B, 63.13M shares outstanding, 140 institutional holders tracked. Key dilution vectors include approximately 50 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
0
📊 Float Risk
35
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for ZBIO.
🔔 Track ZBIO — Get forecast alerts →

💹 Market Data

Market Cap$1.16B
Shares Outstanding63.13M
Float39.62M
Cash$717.21M
Debt$78.64M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 38.0% shares (2026Q1 vs prior)
140 institutional holders · 58.11M shares
#1 FMR LLC 9.08M shares
#2 SR One Capital Management, LP 5.04M shares
#3 NEA Management Company, LLC 4.02M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest12.20M
Days to Cover9.6
% of Float30.8%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2024
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for ZBIO Shareholders

Zenas BioPharma, Inc. (ZBIO) has a DilutionScore of 25/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 14, 2026.

DilutionWatch's EDGAR monitoring for ZBIO shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for ZBIO in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for ZBIO alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track ZBIO Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ZBIO — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for ZBIO
📊 ZBIO FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 ZBIO Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.